Home / Contract Awards / Unisys to Help TSA Operate, Protect Airport Screening Devices Under $250M BPA

Unisys to Help TSA Operate, Protect Airport Screening Devices Under $250M BPA

Unisys (NYSE: UIS) has secured a potential five-year, $250 million blanket purchase agreement to help the Transportation Security Administration operate, maintain and safeguard security screening tools fielded at over 400 U.S. airports.

The company said Monday the Domain Awareness Integrated Network Support Services BPA has a one-year base term and four one-year options and was awarded through TSA’s Security Technology Integrated Program.

Unisys will leverage its portfolio of Stealth microsegmentation software and security offerings to deliver operational and application development support in order to link and integrate data from nearly 14,000 baggage and passenger screening tools and other security devices operated by TSA.

“Through this work of deploying Stealth and developing, implementing and maintaining these mission-critical applications for TSA, Unisys will assist the agency in its ongoing mission to ensure safety for the hundreds of millions of U.S. citizens who rely on air travel every year,” said Amy Rall, group vice president for homeland security and critical infrastructure at Unisys’ federal business.

Unisys’ Stealth offerings work to protect users, applications, data and other information technology systems from cyber threats through the use of microsegmentation technology.

Check Also

F5 to Buy Shape Security for $1B; Francois Locoh-Donou Quoted

F5 Networks (Nasdaq: FFIV) has agreed to acquire Santa Clara, Calif.-based Shape Security for approximately $1B in cash as both companies aim to help government and enterprise customers secure digital experience with integrated offerings.

Paratek Secures $169M Anthrax Antibiotic Development Contract Under HHS Project BioShield

The Department of Health and Human Services has awarded Paratek Pharmaceuticals a potential a five-year, $169M contract to further develop an antibiotic drug as a potential treatment for inhalation anthrax.